Pharming Group N.V. ADR (PHAR) Stock Price, Quote & News

Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated pho...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 71 524 7400

Fax: 31 71 524 7445

Website: www.pharming.com

Address:

Darwinweg 24, Leiden, Netherlands

Ruconestor Oct. 3 at 9:49 AM

$PHAR

0 · Reply

NVDAMillionaire Oct. 3 at 7:21 AM

$PHAR Excellent article that nails exactly where PHAR stands right now. So if you want to update your PHAR knowledge or get acquainted with PHAR, this is a must read. https://beyondspx.com/quote/PHAR/analysis/pharming-s-dual-growth-engines-and-pipeline-propel-rare-disease-leadership-nasdaq-phar

0 · Reply

Ruconestor Oct. 1 at 2:57 PM

$PHAR Aandeel gaat verder knallen. Eindelijk valt alles op z'n plek. Mooi die veiligheid gebleken zelfs voor kleuters!! Wachten is op de diverse andere indicaties Very strong buy for very safe and curing Medicins 👍

0 · Reply

OpenOutcrier Oct. 1 at 12:33 PM

$PHAR (+2.1% pre) Pharming shares up as FDA grants priority review for Joenja in children https://ooc.bz/l/79027

0 · Reply

Gabriel1234 Oct. 1 at 11:13 AM

$PHAR https://www.marketwatch.com/press-release/pharming-group-announces-u-s-fda-acceptance-and-priority-review-of-supplemental-new-drug-application-for-leniolisib-in-children-with-apds-aged-4-to-11-years-1c5a7bca?mod=mw_quote_news_seemore

0 · Reply

Noobnr1 Oct. 1 at 9:19 AM

$NYXH it’s will be a huge company soon 🚀 $GILD $PFE $PHAR Fast judgement by FDA = approval very soon 🥳🥳

0 · Reply

Longterm007 Oct. 1 at 6:14 AM

$PHAR News: Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years https://www.pharming.com/news/pharming-group-announces-us-fda-acceptance-priority-review-supplemental-new-drug-application-leniolisib-pediatric-APDS

0 · Reply

SannieVerraderlijk Sep. 29 at 10:41 AM

$PHAR Recovery from 100% tariff scare.

0 · Reply

Longterm007 Sep. 26 at 12:25 PM

$PHAR Fuck Trump

0 · Reply

ap20 Sep. 26 at 11:28 AM

$PHAR Added early in the US.

0 · Reply

Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years

Sep 10, 2025, 1:00 AM EDT - 25 days ago

Pharming Group promoted to the Euronext AMX® index

Sep 3, 2025, 2:00 AM EDT - 4 weeks ago

Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 1:00 AM EDT - 4 weeks ago

Pharming Group appoints Kenneth Lynard as Chief Financial Officer

Aug 4, 2025, 2:00 AM EDT - 2 months ago

Pharming Group to participate in August investor conference

Aug 1, 2025, 3:04 PM EDT - 2 months ago

Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 1:00 AM EDT - 2 months ago

Pharming Group reports second quarter and first half 2025 financial results and provides business update

Jul 17, 2025, 2:00 AM EDT - 2 months ago

Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31

Jun 24, 2025, 1:00 AM EDT - 3 months ago

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis

Jun 11, 2025, 11:15 AM EDT - 4 months ago

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

May 28, 2025, 2:00 AM EDT - 4 months ago

Pharming Group to participate in June investor conferences

May 9, 2025, 8:50 AM EDT - 5 months ago

Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

May 8, 2025, 1:00 AM EDT - 5 months ago

Pharming Group reports first quarter 2025 financial results and provides business update

Apr 30, 2025, 11:45 AM EDT - 5 months ago

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Apr 24, 2025, 2:00 AM EDT - 5 months ago

Pharming Group to report first quarter 2025 financial results on May 8

Apr 23, 2025, 3:30 AM EDT - 5 months ago

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Apr 3, 2025, 1:00 AM EDT - 6 months ago

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Mar 28, 2025, 3:00 AM EDT - 6 months ago

Pharming Group to participate in April investor conferences

Mar 13, 2025, 7:44 PM EDT - 7 months ago

Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 2:00 AM EDT - 7 months ago

Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

Mar 4, 2025, 9:15 AM EST - 7 months ago

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Feb 7, 2025, 4:00 PM EST - 8 months ago

Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period

Jan 21, 2025, 12:00 PM EST - 9 months ago

Pharming Group to convene Extraordinary General Meeting of Shareholders

Jan 21, 2025, 1:00 AM EST - 9 months ago

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Dec 15, 2024, 1:45 PM EST - 10 months ago

Pharming announces public cash offer to the shareholders of Abliva AB

Dec 11, 2024, 9:34 AM EST - 10 months ago

European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug

Nov 5, 2024, 2:00 AM EST - 11 months ago

Pharming Group to participate in November investor conference

Oct 24, 2024, 1:44 PM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript

Oct 10, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report third quarter 2024 financial results on October 24

Oct 10, 2024, 1:00 AM EDT - 1 year ago

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Sep 26, 2024, 1:00 AM EDT - 1 year ago

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

Sep 4, 2024, 1:00 AM EDT - 1 year ago

Pharming Group to participate in September investor conferences

Aug 2, 2024, 3:26 PM EDT - 1 year ago

Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 1:00 AM EDT - 1 year ago

Pharming Group reports second quarter and first half 2024 financial results and provides business update

Jul 18, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report second quarter and first half 2024 financial results on August 1

May 30, 2024, 4:44 PM EDT - 1 year ago

Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union

May 21, 2024, 11:30 AM EDT - 1 year ago

Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

May 20, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to participate in May investor conference

May 15, 2024, 1:00 AM EDT - 1 year ago

Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025

May 12, 2024, 9:19 AM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript

Apr 24, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report first quarter 2024 financial results on May 8

Apr 24, 2024, 1:00 AM EDT - 1 year ago

Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Apr 19, 2024, 12:43 PM EDT - 1 year ago

Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025

Apr 18, 2024, 9:04 AM EDT - 1 year ago

Pharming Group announces the placement of €100 million convertible bonds due 2029

Apr 18, 2024, 2:00 AM EDT - 1 year ago

Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025

Apr 8, 2024, 1:00 AM EDT - 1 year ago

Pharming announces completion of enrollment in pediatric clinical trial of leniolisib

Apr 4, 2024, 2:30 AM EDT - 1 year ago

Pharming Group announces the 2024 Annual General Meeting of Shareholders

Apr 4, 2024, 1:00 AM EDT - 1 year ago

Pharming Group announces the filing of its 2023 Annual Report and Form 20-F

Mar 14, 2024, 1:15 PM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 2:00 AM EDT - 1 year ago

Pharming Group reports fourth quarter and full year 2023 financial results

Ruconestor Oct. 3 at 9:49 AM

$PHAR

0 · Reply

NVDAMillionaire Oct. 3 at 7:21 AM

0 · Reply

Ruconestor Oct. 1 at 2:57 PM

0 · Reply

OpenOutcrier Oct. 1 at 12:33 PM

$PHAR (+2.1% pre) Pharming shares up as FDA grants priority review for Joenja in children https://ooc.bz/l/79027

0 · Reply

Gabriel1234 Oct. 1 at 11:13 AM

0 · Reply

Noobnr1 Oct. 1 at 9:19 AM

$NYXH it’s will be a huge company soon 🚀 $GILD $PFE $PHAR Fast judgement by FDA = approval very soon 🥳🥳

0 · Reply

Longterm007 Oct. 1 at 6:14 AM

0 · Reply

SannieVerraderlijk Sep. 29 at 10:41 AM

$PHAR Recovery from 100% tariff scare.

0 · Reply

Longterm007 Sep. 26 at 12:25 PM

$PHAR Fuck Trump

0 · Reply

ap20 Sep. 26 at 11:28 AM

$PHAR Added early in the US.

0 · Reply

Ruconestor Sep. 26 at 8:36 AM

$PHAR Irish Trade Minister Harris States EU-US Trade Deal Keeps Pharma Tariffs at 15%, Emphasizes Importance of Agreement

0 · Reply

Ruconestor Sep. 23 at 12:26 PM

$PHAR Organisatiepagina weergeven voor Pharming Group. Pharming Group 14.072 volgers 1 w 📢 We're proud to share that we've been promoted to the Euronext AMX Index. This promotion reflects our strong growth momentum and recognition in the market. It’s a meaningful step that enhances our visibility and further strengthens our profile, especially with the investor community. A big thank you to our team and partners for helping us reach this milestone, and to our investors for their continued confidence 🤝. 👉 Read more: https://bit.ly/3VFcAH4

0 · Reply

ap20 Sep. 14 at 6:54 PM

$PHAR OK European team: hoping your index boys will step up this week to own some PHAR. And good luck to your Ryder Cup team. I have read about the sportsmanship and comradery way back when the matches started. I wish it could get back that way…

0 · Reply

BGG13 Sep. 10 at 2:06 PM

$PHAR

0 · Reply

Ruconestor Sep. 10 at 5:40 AM

$PHAR Pharming Group promoted to the Euronext AMX® index Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective from September 22, 2025.

1 · Reply

ap20 Sep. 3 at 10:19 PM

$PHAR No Comprehend…..OK & UP!

1 · Reply

Longterm007 Sep. 3 at 11:00 AM

$PHAR Houd zelf ook wel van orale toediening

1 · Reply

Longterm007 Sep. 3 at 10:59 AM

$PHAR zijn stelletje kleuters

1 · Reply

Ruconestor Sep. 3 at 10:36 AM

$PHAR Het IEX forum en Henkie de moderator zet zichzelf weer te kakken vandaag. De inzet van hun Jokers sorteren nu juist t tegengestelde effect. IEX gaat behoorlijk nat Met hun potsierlijke gebash😂

0 · Reply

Ruconestor Sep. 3 at 8:13 AM

$PHAR Pipo Monitor denkt dat een orale toediening sneller werkt dan een Intraveneuze toediening.los van het feit nog wat voor stof je toedient. Ruconest is de beste en breedst mogelijke medicatie voor HAE,

1 · Reply

Ruconestor Sep. 3 at 6:49 AM

$PHAR De “stoker-jokers” zijn weer ingezet door IEX op het Pharming Group forum. Meester en Monitor moeten weer voor wat clicks en ergernis zorgen met hun achterlijke gezwets. Wat een soapsite.

0 · Reply

Declan1NL Sep. 2 at 12:54 PM

$PHAR https://www.zacks.com/stock/news/2673250/wall-street-analysts-think-pharming-group-phar-could-surge-145-75-read-this-before-placing-a-bet?cid=CS-STOCKTWITS-HL-tale_of_the_tape%7Cconsensus_price_target-2673250&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_551_2673250

1 · Reply

Market Cap	1.11B
Revenue (ttm)	297.20M
Net Income (ttm)	-11.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3.98%
Debt to Equity Ratio	0.02

Volume	10,600
Avg Vol	13,298
Day's Range	N/A - N/A
Shares Out	68.52M
Stochastic %K	95%
Beta	0.04
Analysts	Strong Sell
Price Target	$30.67